exagen-logo-440x386-1.jpg
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
09. November 2023 16:05 ET | Exagen Inc.
SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the...
exagen-logo-440x386-1.jpg
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
02. November 2023 16:05 ET | Exagen Inc.
SAN DIEGO, California, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Canaccord...
exagen-logo-440x386-1.jpg
Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023
30. Oktober 2023 16:05 ET | Exagen Inc.
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023,...
exagen-logo-440x386-1.jpg
Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting
28. September 2023 16:05 ET | Exagen Inc.
SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023...
exagen-logo-440x386-1.jpg
Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
12. September 2023 16:05 ET | Exagen Inc.
SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor...
exagen-logo-440x386-1.jpg
Exagen Inc. Reports Strong Second Quarter 2023 Results
07. August 2023 08:00 ET | Exagen Inc.
SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2023. ...
exagen-logo-440x386-1.jpg
Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference
26. Juli 2023 16:05 ET | Exagen Inc.
SAN DIEGO, July 26, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 43rd Annual...
exagen-logo-440x386-1.jpg
Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023
25. Juli 2023 16:05 ET | Exagen Inc.
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before...
exagen-logo-440x386-1.jpg
Exagen Inc. Appoints Paul Kim to Board of Directors
24. Juli 2023 16:05 ET | Exagen Inc.
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen...
exagen-logo-440x386-1.jpg
Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference
30. Mai 2023 09:00 ET | Exagen Inc.
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the William Blair 43rd Annual Growth...